In focus: CCGs hail ‘victory for common sense’ after Avastin ruling

A ruling in favour of 12 CCGs is an important win for AMD sufferers and the health service, reports Sean Rai-Roche

The NHS has won a major legal battle over the pharmaceutical industry in the UK High Court. It is likely to a have a significant impact on patients with wet age-related macular degeneration (AMD).

It was discovered a decade ago that off-label bevacizumab – sold under the trade name Avastin – was also effective at treating certain eye conditions. This was confirmed by a number of international clinical trials and is also accepted by the World Health Organisation (WHO). Drugs licensed for ophthalmic use, such as Lucentis, are made from the same molecule as Avastin but command a far higher price.

Register now to continue reading

Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.


Already have an account? Sign in here